Skip to Content

PharMEDium sale a big deal for Oak

FORTUNE — Private equity firm Clayton Dubilier & Rice today said that it has completed its previously-announced acquisition of a majority stake in PharMEDium from Oak Investment Partners and Baird Capital.

No financial terms were disclosed, but Fortune has learned that the deal was done at around a $900 million enterprise valuation.

For Oak this represents around a 6x return on its 2007 investment, when it paid around $67 million to acquire an equity stake from Baird (which retained part of its position).

PharMEDium is a Lake Forrest, Ill.–based provider of hospital pharmacy sterile compounding services.

Sign up for Dan Primack’s daily email newsletter on deals and deal-makers: